Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody (mAb) and vaccines. The biological drugs market is growing due to the increasing prevalence of chronic diseases and the demand for biological drugs is growing due to the increase in the global geriatric population. Moreover, various government associations are also supporting in growth of biological drugs market. Furthermore, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market.

On the other hand, high cost of biologic drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of the biological drugs market.

The report provides in-depth analysis and estimation of the biological drugs market from 2014 to 2020, considering 2013 as the base year for calculation. Additionally, data pertaining to current market dynamics including market drivers, restraints, trends and recent developments has been provided in the biological drugs market report. The global biological drugs market is categorized based on therapeutic protein, monoclonal antibody (mAb), vaccine and geography. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix.

Under geographic analysis, the report identifies and analyses the biological drugs market size and provides forecasts for the markets in North America, Europe, Asia and Rest of the World (RoW). Major players operating in the biological drugs market are Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc. and Biogen Idec. These key market players have been profiled based on attributes such as company overview, recent developments, growth strategies, sustainability and financial overview.

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 Global Biological Drugs Market - Industry Analysis

Chapter 4 Market Trends

Chapter 5 Porter's Five Forces Analysis

Chapter 6 Global Market Size and Forecast

Chapter 7 Segment Analysis, by Therapeutic Protein

Chapter 8 Segment Analysis, by mAb

Chapter 9 Segment Analysis, by Vaccine

Chapter 10 Regional Analysis

Chapter 11 Pipeline Biologic Drugs

Chapter 12 Competitive Landscape

Chapter 13 Company Profiles

Companies Mentioned:

• Abbott Laboratories
• Amgen Inc.
• Baxter International Inc.
• Biogen Idec
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline plc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.

For more information visit http://www.researchandmarkets.com/research/kpr76z/biological_drugs

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net